Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens
- 1 October 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28) , 6982-6991
- https://doi.org/10.1200/jco.2005.06.679
Abstract
Purpose To determine whether promising results from phase II studies could be reproduced in phase III studies, and to examine which characteristics of phase II studies might be of predictive value for subsequent phase III studies. Methods We searched for all phase III studies of chemotherapy in advanced solid malignancies, published in the English language literature from July 1998 to June 2003. Each phase III study was reviewed to identify preceding phase II studies. Phase II and phase III studies included in this analysis must have used identical regimens. Data were extracted from both phase II and phase III studies. Results Of 181 phase III studies identified, 43 used therapeutic regimens identical to those in 49 preceding phase II studies. Twelve phase III studies (28%) were “positive.” The vast majority (81%) of phase III studies have lower response rates than preceding phase II studies, with a mean difference of 12.9% among all studies analyzed. None of the phase II study characteristics evaluated significantly predicted for “positive” phase III studies, but the sample size of phase II studies demonstrated a trend toward being predictive (P = .083). Conclusion Promising results from phase II studies frequently do not translate into “positive” phase III studies. Response rates in most phase III studies are lower than those in preceding phase II studies.Keywords
This publication has 26 references indexed in Scilit:
- Beyond Fast Track for Drug ApprovalsNew England Journal of Medicine, 2004
- The Costs of Conducting Clinical ResearchJournal of Clinical Oncology, 2003
- Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth”Journal of Cardiac Failure, 2003
- The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” DecisionJournal of Clinical Oncology, 2003
- Selection bias, phase II trials, and the FDA accelerated approval process.JNCI Journal of the National Cancer Institute, 2003
- Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort StudyJournal of Clinical Oncology, 2002
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering ResultsJournal of Clinical Oncology, 2001
- Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible ProgressJournal of Clinical Oncology, 1999
- A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology.Journal of Clinical Oncology, 1994
- Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.Journal of Clinical Oncology, 1994